share_log

HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $54 Price Target

Benzinga ·  Oct 4, 2023 06:16

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates UroGen Pharma (NASDAQ:URGN) with a Buy and maintains $54 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment